HomeTrading IdeasEurozone Economic Weakness Laid...

Eurozone Economic Weakness Laid Bare as US Front-Loading Effects Wane

Eurozone data remains volatile amid trade war developments, but the underlying trend is still sluggish. Uncertainty is slowing domestic demand, which contributes to our expectation of a further rate cut from the European Central Bank in September

Eurozone Economy Shows Further Weakness in the Second Quarter

The eurozone economy had been inflated in the first quarter by strong US front-loading effects. Pharma, in particular, saw a significant boost to exports, but other sectors also profited from Americans trying to avoid higher costs for goods. The 0.6% quarter-on-quarter growth rate was the best since the second quarter of 2022, but April industrial production and trade figures poured cold water on any hopes of sustained strength. Production and exports fell by 2.4% and 8.2% respectively, suggesting that the reversal of front-loading effects is now weighing negatively on second-quarter growth.

And the second quarter is also plagued by subdued domestic demand, which leads us to believe that a negative growth print for the period is likely. Services production was down by -0.3% month-on-month in April, and retail sales fell by 0.7% in May. While the timing of holidays may have influenced activity data throughout the second quarter, weakness in the service sector has become a theme in the eurozone in recent months.

In 2Q, Eurozone Services Sentiment Hit Its Lowest Level Since 2013, Excluding the Pandemic

Source: European Commission DG ECFIN

Fearful Consumers and Businesses Weigh on Domestic Demand

For the third quarter, we expect stagnation compared to the second quarter. We don’t expect a full escalation of trade tensions, but a continuation of current uncertainty and trade barriers that could still tick higher from where we are now. The continuation of the “tariff pause” for a few more weeks is unlikely to bring significant relief to the eurozone domestic economy, instead extending a period of uncertainty around the economic outlook for the bloc.

The uncertainty not only makes our lives as forecasters more difficult, but it is also weighing on domestic demand. It is likely an important reason for the sluggish service sector performance in the second quarter. Franklin Roosevelt warned us of this decades ago, but his statement that the “only thing to fear is fear itself” could be falling on deaf ears in the eurozone as economic activity seems increasingly hampered by worried businesses and consumers.

The household savings rate remains at very high levels, which has so far dampened a recovery for consumption. As wage growth still outpaces inflation and employment remains near historical lows, stronger consumer spending could have been expected. But weakness remains.

Chances of a Short-lived ECB Pause Are Increasing

Inflationary pressures have clearly eased, with a fast drop in services inflation reflecting weak domestic demand, low energy prices and a stronger euro. We therefore expect inflation to undershoot the ECB’s 2% target in the coming quarters, and we see the ECB cutting rates one more time in September before pausing indefinitely.

We don’t think the current economy requires the central bank to go much lower than the current 2% on the deposit rate. With substantial public investment starting to trickle through to the economy from next year on, the medium-term inflation outlook is likely to remain around 2%. The current environment of huge uncertainty and lack of direction will likely be followed by activity picking up slowly but surely as public investments make a return to the eurozone at long last.

Disclaimer: This publication has been prepared by ING solely for information purposes, irrespective of a particular user’s means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Read more

Original Post

Most Popular

More from Author

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But...

Read Now

Gold Prices Rise on Trump’s Tariff Threats and Fed Policy Uncertainty

Tariff-Related Inflation Risks Support Gold Gold () rose by over 0.35% on Wednesday. Markets remain focused on tariff demand letters from US President Donald Trump, with Brazil the latest country to face steep duties on and other imports. The tariffs have fuelled concerns about broader trade disruptions and...

FDA Grants Complete Approval To Moderna’s COVID-19 Vaccine For Children As Young As 6 Months – Moderna (NASDAQ:MRNA)

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.The company’s COVID-19 vaccine, mRNA-1273, was previously available...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But only mild risk aversion as Nvidia (NASDAQ:) drives equities higher, hits $4 trillion cap Fed minutes erase July cut bets as doves in the minority, dollar supported Bitcoin hits record high, comes just shy of $112,000 Trump Stuck in...

The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025 – Global X MSCI Greece ETF (ARCA:GREK), Invesco QQQ Trust, Series 1...

Greece's 2010 collapse was so severe it leased islands, gutted public jobs and pensions, while some abroad even joked about selling the Acropolis to appease creditors.Fast forward 15 years, and the picture couldn't be more different.The Athens Stock Exchange has soared nearly 34% year-to-date, making Greece the...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation fears are wide of the mark. The Fed will likely delay rate cuts until the end of the year, despite escalating pressure from the president, but may move in larger steps when it does cutConsumer Caution...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.“Multispecifics including trispecific antibodies represent...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can lead to significant drag in performance for currencies with negative carry. However, not hedging the foreign currency exposure can lead to significant drawdowns, especially for conservative investments. In this paper, we consider a conservative, global tactical...

German CPI Confirmed at 2.0%, Euro Drifting, FOMC Split Over Cuts

The euro continues to have a quiet week and is drifting for a third consecutive day. In the European session, is trading at 1.1730, up 0.09% on the day.German Inflation Dips to 2% as food, Energy Prices FallGerman inflation rose 2.0% y/y in June, in line...

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? – Klotho Neurosciences (NASDAQ:KLTO)

Shares of Klotho Neurosciences, Inc. KLTO have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate. What's Driving The Rally: Klotho announced it has received...

SeaStar Medical’s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka – Johnson & Johnson...

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58%. Many of those...

Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? – Ultragenyx Pharmaceutical (NASDAQ:RARE), Mereo BioPharma Group (NASDAQ:MREO)

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.What Happened?The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward...